Anap­tys­Bio drops an­oth­er in­di­ca­tion for lead drug af­ter it fails a sec­ond PhII study in 12 months

Anap­tys­Bio’s lead drug has failed an­oth­er mid-stage study, lead­ing to its dis­con­tin­u­a­tion in ac­ne.

The biotech re­vealed Mon­day af­ter­noon that its an­ti-IL-36R an­ti­body im­si­dolimab did …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER